Variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome: pharmacogenetic aspect-Reference-Cited by-同舟云学术

Variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome: pharmacogenetic aspect

Published:2019-12-09 Issue:4-1 Volume: Page:118-121
ISSN:2313-7053
Container-title:V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
language:
Short-container-title:V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY

Author:

Palatkin V. Ya¹,Kibitov A. O.²,Krupitsky Е. M.³,Blokhina Е.A. Е. A.¹,Brodyansky V. M⁴,Verbitskaya Е. V.¹,Zvartau E. E.¹

Affiliation:

1. First Pavlov State Medical University

2. Serbsky Federal Medical Research Centre of Psychiatry and Narcology; Bekhterev National Medical Research Center for Psychiatry and Neurology

3. First Pavlov State Medical University; Bekhterev National Medical Research Center for Psychiatry and Neurology

4. Serbsky Federal Medical Research Centre of Psychiatry and Narcology

Abstract

There is a problem of insufficient effectiveness of pharmacotherapy for the relapse prevention in patients with opioid dependence. In Russian Federation naltrexone is a mainly used medication for treatment of opioid addiction. However, it has no effects on stress, craving, and impulsiveness. Alpha-2 adrenoreceptor agonists can reduce the severity of these symptoms and thus might improve effectiveness of naltrexone treatment. Pharmacogenetic analysis is useful for determining potential responders and nonresponders to the treatment of opioid dependence. The aim of this study was to evaluate the variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome. This was a multicenter, randomized, double-blind, placebo-controlled clinical trial using a pharmacogenetic approach. The good tolerability and safety of naltrexone and guanfacine combination with long-term course treatment for stabilization of remission of opioid dependence was scientifically substantiated. Was showed a moderate stress-protective and anti-craving effect of guanfacin in the period of early remission with opioid dependence syndrome. Genetic analysis is useful for determining potential responders to the treatment of opioid dependence, genotyping can increase effectiveness of pharmacotherapy.

Publisher

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

Reference13 articles.

1. Vinnikova MA, Illarionova YuV. Pharmacoeconomic analysis in addiction practice: excess or need? Voprosy narkologii. 2012;5:78–95. (In Russ).

2. Ivanecz NN, Kkshkina EA, Kirzhanova VV, Gurtovenko VM, Pavlovskaya NI, Xodyrev VA, Klevno VA, Solomatin EM, Lisyanskij BM. Smertnost bolnyx narkomaniej v rossijskoj federacii. Analiz dannyx federalnogo statisticheskogo nablyudeniya. Voprosy narkologii. 2008;3:105-118. (In Russ).

3. Kibitov AO. Pharmacogenetics of substance dependence disorders. Narkologiya. 2015;11:61–74. (In Russ).

4. Kibitov AO. Clinical and therapeutic aspects of addiction. Voprosy narkologii. 2016;3:3–29. (In Russ).

5. Kukes VG, Sychev DA, Gasanov IA. Presentday problems of clinical pharmacogenetics. Klinicheskaya medicina. 2007;85(2):58–63. (In Russ).